Inventiva (NASDAQ:IVA) Stock Crosses Below Fifty Day Moving Average - Should You Sell?

Inventiva logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Inventiva shares fell below their 50-day moving average, trading as low as $3.30 versus a 50-day average of $3.61; the last reported price was $3.315.
  • Analyst views were mixed, but MarketBeat’s consensus was “Moderate Buy” with a $14.67 price target. One analyst rated the stock Strong Buy, seven Buy, and one Sell.
  • Inventiva is developing lanifibranor for MASH, with Phase 3 trial topline results expected in Q4 2026. Several institutional investors increased their holdings in the third quarter.
  • Five stocks we like better than Inventiva.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) crossed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $3.61 and traded as low as $3.30. Inventiva shares last traded at $3.3150, with a volume of 2,471,049 shares trading hands.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Wall Street Zen upgraded Inventiva from a "sell" rating to a "hold" rating in a report on Saturday, October 3rd. Weiss Ratings cut shares of Inventiva from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday. Piper Sandler reiterated an "overweight" rating on shares of Inventiva in a research report on Wednesday, September 16th. Guggenheim raised their price target on shares of Inventiva from $11.00 to $14.00 and gave the stock a "buy" rating in a research note on Tuesday, September 15th. Finally, HC Wainwright lowered their price target on shares of Inventiva to $14.00 and set a "buy" rating on the stock in a research report on Thursday, November 5th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Inventiva has an average rating of "Moderate Buy" and a consensus target price of $14.67.

View Our Latest Research Report on IVA

Inventiva Price Performance

The firm has a fifty day moving average of $3.61 and a 200 day moving average of $4.74.

Inventiva (NASDAQ:IVA - Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The company had revenue of $0.75 million during the quarter. Research analysts forecast that Inventiva S.A. Sponsored ADR will post -0.75 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. raised its stake in Inventiva by 64.2% during the third quarter. Goldman Sachs Group Inc. now owns 368,669 shares of the company's stock worth $1,360,000 after purchasing an additional 144,170 shares during the period. Lighthouse Investment Partners LLC acquired a new position in Inventiva in the 3rd quarter valued at about $306,000. Marshall Wace LLP boosted its holdings in Inventiva by 134.2% in the 3rd quarter. Marshall Wace LLP now owns 2,262,530 shares of the company's stock valued at $8,349,000 after purchasing an additional 1,296,623 shares during the last quarter. Nantahala Capital Management LLC grew its stake in shares of Inventiva by 11.9% in the 3rd quarter. Nantahala Capital Management LLC now owns 3,004,859 shares of the company's stock valued at $11,088,000 after buying an additional 318,466 shares during the period. Finally, Aberdeen Group plc grew its stake in shares of Inventiva by 36.3% in the 3rd quarter. Aberdeen Group plc now owns 3,145,711 shares of the company's stock valued at $11,608,000 after buying an additional 837,938 shares during the period. Institutional investors and hedge funds own 19.06% of the company's stock.

Inventiva Company Profile

(Get Free Report)

Inventiva S.A. is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders. Inventiva's lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial. The company expects topline trial results in Q4 2026 and, if results are positive, plans to pursue U.S. regulatory approval, with a potential commercial launch in 2028.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Inventiva Right Now?

Before you consider Inventiva, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.

While Inventiva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines